Cytokinetics, Incorporated (CYTK): Price and Financial Metrics

CYTK POWR Grades

• Growth is the dimension where CYTK ranks best; there it ranks ahead of 48.86% of US stocks.
• The strongest trend for CYTK is in Growth, which has been heading up over the past 177 days.
• CYTK ranks lowest in Sentiment; there it ranks in the 15th percentile.

CYTK Stock Summary

• With a price/sales ratio of 298.55, CYTOKINETICS INC has a higher such ratio than 98.75% of stocks in our set.
• Equity multiplier, or assets relative to shareholders' equity, comes in at -5.48 for CYTOKINETICS INC; that's greater than it is for only 3.23% of US stocks.
• As for revenue growth, note that CYTK's revenue has grown -93.42% over the past 12 months; that beats the revenue growth of merely 1.27% of US companies in our set.
• If you're looking for stocks that are quantitatively similar to CYTOKINETICS INC, a group of peers worth examining would be FULC, ADVM, LYRA, SAGE, and BPMC.
• Visit CYTK's SEC page to see the company's official filings. To visit the company's web site, go to www.cytokinetics.com.

CYTK Valuation Summary

• In comparison to the median Healthcare stock, CYTK's price/sales ratio is 15610.53% higher, now standing at 298.5.
• Over the past 236 months, CYTK's price/earnings ratio has gone up 7.3.

Below are key valuation metrics over time for CYTK.

CYTK Growth Metrics

The 3 year cash and equivalents growth rate now stands at 192.88%.
• Its 4 year net cashflow from operations growth rate is now at -380.62%.
• Its 3 year net cashflow from operations growth rate is now at -42.21%.

Over the past 33 months, CYTK's revenue has gone up $121,363,000.

The table below shows CYTK's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	148.231	-246.063	-282.145
2022-06-30	151.153	-200.793	-215.921
2022-03-31	65.028	-139.814	-257.655
2021-12-31	70.428	-142.522	-215.314
2021-09-30	21.55	-45.635	-228.674
2021-06-30	57.801	7.502	-155.763

CYTK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CYTK has a Quality Grade of C, ranking ahead of 30.43% of graded US stocks.
• CYTK's asset turnover comes in at 0.108 -- ranking 258th of 682 Pharmaceutical Products stocks.
• VRTX, INBP, and MBIO are the stocks whose asset turnover ratios are most correlated with CYTK.

The table below shows CYTK's key quality metrics over time.